作者
Christopher M. Jackson,Ayush Pant,Wikum Dinalankara,John Choi,Aanchal Jain,Ryan T. Nitta,Eli Yazigi,Laura Saleh,Yang Yang,Thomas R. Nirschl,Christina M. Kochel,Brandon H. Bergsneider,Denis Routkevitch,Kisha Patel,Kwang Bog Cho,Stephany Y. Tzeng,Sarah Y. Neshat,Young‐Hoon Kim,Barbara J. Smith,María C. Ramello,Elena Sotillo,Xinnan Wang,Jordan J. Green,Chetan Bettegowda,Gordon Li,Henry Brem,Crystal L. Mackall,Drew M. Pardoll,Charles G. Drake,Luigi Marchionni,Michael Lim
摘要
Highlights•METRNL is more highly expressed in CD8+ TIL than patient-matched PBMCs•METRNL exposure causes CD8+ T cell hypofunction due to bioenergetic insufficiency•METRNL decouples the electron transport chain in T cell mitochondria via E2F-PPARδ•METRNL ablation or knockdown delays tumor growth in tumor modelsSummaryTumor-infiltrating lymphocyte (TIL) hypofunction contributes to the progression of advanced cancers and is a frequent target of immunotherapy. Emerging evidence indicates that metabolic insufficiency drives T cell hypofunction during tonic stimulation, but the signals that initiate metabolic reprogramming in this context are largely unknown. Here, we found that Meteorin-like (METRNL), a metabolically active cytokine secreted by immune cells in the tumor microenvironment (TME), induced bioenergetic failure of CD8+ T cells. METRNL was secreted by CD8+ T cells during repeated stimulation and acted via both autocrine and paracrine signaling. Mechanistically, METRNL increased E2F-peroxisome proliferator-activated receptor delta (PPARδ) activity, causing mitochondrial depolarization and decreased oxidative phosphorylation, which triggered a compensatory bioenergetic shift to glycolysis. Metrnl ablation or downregulation improved the metabolic fitness of CD8+ T cells and enhanced tumor control in several tumor models, demonstrating the translational potential of targeting the METRNL-E2F-PPARδ pathway to support bioenergetic fitness of CD8+ TILs.Graphical abstract